"N Engl J Med"[journal] 检索结果

4461. Trial of Intravenous Immune Globulin in Dermatomyositis. Reply.

作者: Rohit Aggarwal.;Christina Charles-Schoeman.;Joachim Schessl.
来源: N Engl J Med. 2023年388卷1期94-95页

4462. Trial of Intravenous Immune Globulin in Dermatomyositis.

作者: Victoria P Werth.;David F Fiorentino.;Ruth Ann Vleugels.
来源: N Engl J Med. 2023年388卷1期94页

4463. Audio Interview: The Expanding Arsenal of Oral Agents to Treat Covid-19.

作者: Eric J Rubin.;Lindsey R Baden.;Stephen Morrissey.
来源: N Engl J Med. 2023年388卷1期e7页

4464. More COACHing Needed to Optimize Care after Heart Failure Hospitalization.

作者: Parag Goyal.;Evelyn M Horn.
来源: N Engl J Med. 2023年388卷1期82-83页

4465. Moving the Needle on Alzheimer's Disease with an Anti-Oligomer Antibody.

作者: Sam Gandy.;Michelle E Ehrlich.
来源: N Engl J Med. 2023年388卷1期80-81页

4466. A Stormy Heart.

作者: Allison Kratka.;Usha B Tedrow.;Richard N Mitchell.;Amy L Miller.;Joseph Loscalzo.
来源: N Engl J Med. 2023年388卷1期71-78页

4467. Acromegaly.

作者: Joshua Weinreb.;Shitij Arora.
来源: N Engl J Med. 2023年388卷1期70页

4468. New Approaches to Chronic Hepatitis B.

作者: Geoffrey Dusheiko.;Kosh Agarwal.;Mala K Maini.
来源: N Engl J Med. 2023年388卷1期55-69页

4469. Multiple Cerebral Hemorrhages in a Patient Receiving Lecanemab and Treated with t-PA for Stroke.

作者: Nicholas J Reish.;Pouya Jamshidi.;Brian Stamm.;Margaret E Flanagan.;Elizabeth Sugg.;Mengxuan Tang.;Kelly L Donohue.;Matthew McCord.;Chase Krumpelman.;Marek-Marsel Mesulam.;Rudolph Castellani.;Sherry H-Y Chou.
来源: N Engl J Med. 2023年388卷5期478-479页

4470. Locomotor Brachii Sign in Aortic Regurgitation.

作者: Gonzalo Barge-Caballero.;Cayetana Barbeito-Caamaño.
来源: N Engl J Med. 2023年388卷1期e1页

4471. Evidence over Politics - The U.S. Preventive Services Task Force.

作者: Barron H Lerner.;Graham Curtiss-Rowlands.
来源: N Engl J Med. 2023年388卷1期3-5页

4472. Death by Ableism.

作者: Megan A Morris.
来源: N Engl J Med. 2023年388卷1期5-7页

4473. Drug Sensitivity of Currently Circulating Mpox Viruses.

作者: Denisa Bojkova.;Marco Bechtel.;Tamara Rothenburger.;Katja Steinhorst.;Nadja Zöller.;Stefan Kippenberger.;Julia Schneider.;Victor M Corman.;Hannah Uri.;Mark N Wass.;Gaby Knecht.;Pavel Khaykin.;Timo Wolf.;Sandra Ciesek.;Holger F Rabenau.;Martin Michaelis.;Jindrich Cinatl.
来源: N Engl J Med. 2023年388卷3期279-281页

4474. VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19.

作者: Zhujun Cao.;Weiyi Gao.;Hong Bao.;Haiyan Feng.;Shuya Mei.;Peizhan Chen.;Yueqiu Gao.;Zhilei Cui.;Qin Zhang.;Xianmin Meng.;Honglian Gui.;Weijing Wang.;Yimei Jiang.;Zijia Song.;Yiqing Shi.;Jing Sun.;Yifei Zhang.;Qing Xie.;Yiping Xu.;Guang Ning.;Yuan Gao.;Ren Zhao.
来源: N Engl J Med. 2023年388卷5期406-417页

Nirmatrelvir-ritonavir has been authorized for emergency use by many countries for the treatment of coronavirus disease 2019 (Covid-19). However, the supply falls short of the global demand, which creates a need for more options. VV116 is an oral antiviral agent with potent activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

4475. Protection against Omicron from Vaccination and Previous Infection. Reply.

作者: Elizabeth T Chin.;Jeremy D Goldhaber-Fiebert.
来源: N Engl J Med. 2023年388卷1期96页

4476. Protection against Omicron from Vaccination and Previous Infection.

作者: Jessie Zeng.;Joshua Szanyi.;Tony Blakely.
来源: N Engl J Med. 2023年388卷1期95-96页

4477. Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster.

作者: Meredith E Davis-Gardner.;Lilin Lai.;Bushra Wali.;Hady Samaha.;Daniel Solis.;Matthew Lee.;Andrea Porter-Morrison.;Ian T Hentenaar.;Fumiko Yamamoto.;Sucheta Godbole.;Yuan Liu.;Daniel C Douek.;Frances Eun-Hyung Lee.;Nadine Rouphael.;Alberto Moreno.;Benjamin A Pinsky.;Mehul S Suthar.
来源: N Engl J Med. 2023年388卷2期183-185页

4478. Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C.

作者: Rona Yaeger.;Jared Weiss.;Meredith S Pelster.;Alexander I Spira.;Minal Barve.;Sai-Hong I Ou.;Ticiana A Leal.;Tanios S Bekaii-Saab.;Cloud P Paweletz.;Grace A Heavey.;James G Christensen.;Karen Velastegui.;Thian Kheoh.;Hirak Der-Torossian.;Samuel J Klempner.
来源: N Engl J Med. 2023年388卷1期44-54页

Adagrasib, an oral small-molecule inhibitor of mutant KRAS G12C protein, has shown clinical activity in pretreated patients with several tumor types, including colorectal cancer. Preclinical studies suggest that combining a KRAS G12C inhibitor with an epidermal growth factor receptor antibody could be an effective clinical strategy.

4479. Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer.

作者: John H Strickler.;Hironaga Satake.;Thomas J George.;Rona Yaeger.;Antoine Hollebecque.;Ignacio Garrido-Laguna.;Martin Schuler.;Timothy F Burns.;Andrew L Coveler.;Gerald S Falchook.;Mark Vincent.;Yu Sunakawa.;Laetitia Dahan.;David Bajor.;Sun-Young Rha.;Charlotte Lemech.;Dejan Juric.;Marko Rehn.;Gataree Ngarmchamnanrith.;Pegah Jafarinasabian.;Qui Tran.;David S Hong.
来源: N Engl J Med. 2023年388卷1期33-43页

KRAS p.G12C mutation occurs in approximately 1 to 2% of pancreatic cancers. The safety and efficacy of sotorasib, a KRAS G12C inhibitor, in previously treated patients with KRAS p.G12C-mutated pancreatic cancer are unknown.

4480. Protecting the Public Health with the Inflation Reduction Act - Provisions Affecting Climate Change and Its Health Effects.

作者: Robert L Glicksman.
来源: N Engl J Med. 2023年388卷1期84-88页

结果排序

文献格式

出版时间

出版类型

出版语言